Amgen Inc. (NASDAQ:AMGN) had its price target upped by stock analysts at BMO Capital Markets to $212.00 in a note issued to investors on Monday. BMO Capital Markets’ price objective would suggest a potential upside of 26.27% from the company’s previous close.
Other equities research analysts also recently issued research reports about the stock. RBC Capital Markets set a $190.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Sunday, October 30th. Argus set a $195.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Saturday. Chardan Capital upgraded shares of Amgen from a “sell” rating to a “neutral” rating in a research report on Tuesday, December 13th. Vetr downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $167.77 target price for the company. in a research report on Thursday, November 10th. Finally, Mizuho restated a “buy” rating on shares of Amgen in a report on Wednesday, February 8th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the stock. Amgen currently has an average rating of “Hold” and an average target price of $181.47.
Amgen (NASDAQ:AMGN) opened at 167.89 on Monday. The stock has a market capitalization of $123.90 billion, a price-to-earnings ratio of 16.40 and a beta of 1.15. Amgen has a 12 month low of $133.64 and a 12 month high of $176.85. The company has a 50-day moving average price of $156.34 and a 200 day moving average price of $159.35.
Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, February 2nd. The medical research company reported $2.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.10. Amgen had a net margin of 33.59% and a return on equity of 29.42%. The company earned $5.97 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the firm earned $2.61 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Equities analysts predict that Amgen will post $12.34 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 8th. Shareholders of record on Wednesday, February 15th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Monday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $1.00. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s payout ratio is currently 39.06%.
WARNING: This story was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this story on another site, it was stolen and republished in violation of United States & international trademark & copyright laws. The legal version of this story can be viewed at http://sleekmoney.com/amgen-inc-amgn-price-target-raised-to-212-00-at-bmo-capital-markets/1657727.html.
Several institutional investors have recently made changes to their positions in the company. New York Life Trust Co. increased its position in shares of Amgen by 54.8% in the third quarter. New York Life Trust Co. now owns 624 shares of the medical research company’s stock worth $104,000 after buying an additional 221 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Amgen by 100.0% in the third quarter. Penserra Capital Management LLC now owns 684 shares of the medical research company’s stock worth $114,000 after buying an additional 342 shares in the last quarter. Oakworth Capital Inc. increased its position in shares of Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock worth $119,000 after buying an additional 10 shares in the last quarter. Nelson Roberts Investment Advisors LLC bought a new position in shares of Amgen during the third quarter worth $123,000. Finally, Integrated Wealth Management increased its position in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. 79.04% of the stock is owned by institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amgen-inc-amgn-price-target-raised-to-212-00-at-bmo-capital-markets/1657727.html
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.